MedTrace Logo

A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males

NCT05396235 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-01-18

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics when MT-3921 or a placebo is intravenously given to Japanese healthy adult male subjects

Conditions

  • Healthy Adult Males

Interventions

BIOLOGICAL

MT-3921

Solution for infusion; Intravenous (IV)

BIOLOGICAL

Placebo

Solution for infusion; Intravenous (IV)

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • General Manager · Mitsubishi Tanabe Pharma Corporation

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-03
Primary Completion
2022-12-24
Completion
2022-12-24
FDA Drug
Yes

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05396235 on ClinicalTrials.gov